dc.contributor.author |
Sheikh-Taha M. |
dc.contributor.author |
Koussa S. |
dc.contributor.author |
Inati A. |
dc.contributor.author |
Taher A. |
dc.contributor.editor |
|
dc.date |
Oct-2007 |
dc.date.accessioned |
2017-10-05T15:37:25Z |
dc.date.available |
2017-10-05T15:37:25Z |
dc.date.issued |
2007 |
dc.identifier |
10.1080/03630260701641211 |
dc.identifier.isbn |
|
dc.identifier.issn |
03630269 |
dc.identifier.uri |
http://hdl.handle.net/10938/15701 |
dc.description.abstract |
A 36-year-old transfusion-dependent thalassemia major patient presented with febrile neutropenia and anemia. Deferiprone (L1) was discontinued as it was suspected to be the offending agent and prompt broad-spectrum antibiotic therapy was initiated after which the patient improved. After 11 days the patient developed hemorrhagic stroke and seizure whereby aspirin was discontinued and supportive therapy was given. Agranulocytosis is the most serious complication reported with L1 but, to the best of our knowledge, there are no previous reports on hemorrhagic stroke associated with the use of the agent, and hence, the etiology of the stroke which followed agranulocytosis caused by L1 remains obscure. Copyright © Informa Healthcare USA, Inc. |
dc.format.extent |
|
dc.format.extent |
Pages: (499-501) |
dc.language |
English |
dc.publisher |
PHILADELPHIA |
dc.relation.ispartof |
Publication Name: Hemoglobin; Publication Year: 2007; Volume: 31; no. 4; Pages: (499-501); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient |
dc.type |
Article |
dc.contributor.affiliation |
Sheikh-Taha, M., Lebanese American University, Byblos, Lebanon |
dc.contributor.affiliation |
Koussa, S., Chronic Care Center, Hazmieh, Lebanon |
dc.contributor.affiliation |
Inati, A., Chronic Care Center, Hazmieh, Lebanon |
dc.contributor.affiliation |
Taher, A., Chronic Care Center, Hazmieh, Lebanon, American University of Beirut Medical Center, Beirut, Lebanon, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, P.O. Box 11-0236, Riad El Solh 1107 2020, Lebanon |
dc.contributor.authorAddress |
Taher, A.; Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; email: ataher@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
ataher@aub.edu.lb |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Sheikh-Taha, M |
dc.contributor.authorInitials |
Koussa, S |
dc.contributor.authorInitials |
Inati, A |
dc.contributor.authorInitials |
Taher, A |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Taher, A (reprint author), Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
ALREFAIE FN, 1995, BRIT J HAEMATOL, V91, P224, DOI 10.1111-j.1365-2141.1995.tb05274.x; ALREFAIE FN, 1992, BLOOD, V80, P593; Ceci A, 2002, BRIT J HAEMATOL, V118, P330, DOI 10.1046-j.1365-2141.2002.03554.x; Cohen AR, 2003, BLOOD, V102, P1583, DOI 10.1182-blood-2002-10-3280; Thrift AG, 1999, BRIT MED J, V318, P759 |
dc.description.citedCount |
1 |
dc.description.citedTotWOSCount |
2 |
dc.description.citedWOSCount |
2 |
dc.format.extentCount |
3 |
dc.identifier.articleNo |
|
dc.identifier.coden |
HEMOD |
dc.identifier.pubmedID |
17994386 |
dc.identifier.scopusID |
36248991398 |
dc.identifier.url |
|
dc.publisher.address |
325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Hemoglobin |
dc.relation.ispartOfIssue |
4 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Hemoglobin |
dc.relation.ispartofPubTitleAbbr |
Hemoglobin |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
31 |
dc.source.ID |
WOS:000250921600014 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Deferiprone (L1) |
dc.subject.otherAuthKeyword |
Febrile neutropenia |
dc.subject.otherAuthKeyword |
Hemorrhagic stroke |
dc.subject.otherAuthKeyword |
Thalassemia major |
dc.subject.otherChemCAS |
acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1 |
dc.subject.otherChemCAS |
cefepime, 88040-23-7 |
dc.subject.otherChemCAS |
deferiprone, 30652-11-0 |
dc.subject.otherChemCAS |
phenytoin, 57-41-0, 630-93-3 |
dc.subject.otherChemCAS |
recombinant granulocyte colony stimulating factor, 121181-53-1 |
dc.subject.otherChemCAS |
teicoplanin, 61036-62-2, 61036-64-4 |
dc.subject.otherChemCAS |
valproic acid, 1069-66-5, 99-66-1 |
dc.subject.otherChemCAS |
deferiprone, 30652-11-0 |
dc.subject.otherChemCAS |
Iron Chelating Agents |
dc.subject.otherChemCAS |
Pyridones |
dc.subject.otherIndex |
acetylsalicylic acid |
dc.subject.otherIndex |
antibiotic agent |
dc.subject.otherIndex |
cefepime |
dc.subject.otherIndex |
deferiprone |
dc.subject.otherIndex |
granulocyte colony stimulating factor receptor |
dc.subject.otherIndex |
phenytoin |
dc.subject.otherIndex |
recombinant granulocyte colony stimulating factor |
dc.subject.otherIndex |
teicoplanin |
dc.subject.otherIndex |
valproic acid |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
agranulocytosis |
dc.subject.otherIndex |
anamnesis |
dc.subject.otherIndex |
anemia |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
blood cell count |
dc.subject.otherIndex |
blood culture |
dc.subject.otherIndex |
blood transfusion |
dc.subject.otherIndex |
brain angiography |
dc.subject.otherIndex |
brain hemorrhage |
dc.subject.otherIndex |
case report |
dc.subject.otherIndex |
computer assisted tomography |
dc.subject.otherIndex |
drug substitution |
dc.subject.otherIndex |
drug withdrawal |
dc.subject.otherIndex |
febrile neutropenia |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
hemorrhagic stroke |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
laboratory test |
dc.subject.otherIndex |
leukocyte count |
dc.subject.otherIndex |
seizure |
dc.subject.otherIndex |
stroke |
dc.subject.otherIndex |
thalassemia major |
dc.subject.otherIndex |
throat culture |
dc.subject.otherIndex |
treatment outcome |
dc.subject.otherIndex |
urine culture |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Agranulocytosis |
dc.subject.otherIndex |
beta-Thalassemia |
dc.subject.otherIndex |
Blood Transfusion |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Intracranial Hemorrhages |
dc.subject.otherIndex |
Iron Chelating Agents |
dc.subject.otherIndex |
Neutropenia |
dc.subject.otherIndex |
Pyridones |
dc.subject.otherIndex |
Splenectomy |
dc.subject.otherKeywordPlus |
DEFERIPRONE |
dc.subject.otherKeywordPlus |
THERAPY |
dc.subject.otherKeywordPlus |
SAFETY |
dc.subject.otherWOS |
Biochemistry and Molecular Biology |
dc.subject.otherWOS |
Hematology |